Patent and Access Characteristics of First Line Antiretroviral Drugs in Sub-Saharan African Countries

aSource of data: [11], [12]
bSource of data: [14] The status of certain patents may have changed since publication, due to the failure to pay renewal fees, for instance. This would lend further support to the apparent brand company shift away from enforcement of patents in Sub-Saharan Africa.
cTotal Countries = 38 countries in which transactions reported
dCalculation performed on the basis of countries that had transactions in that drug category (n = 24-31 countries). Number of countries in which drug patented with 0% generic purchases = 5 (AZT+3TC), 2 (3TC), 2 (NVP), 2 (AZT), 1 (d4T), 1 (EFV).
eThe expiry date of the US patent on AZT was September 2005 [11].